1. Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 2010; 94: 835-52.
2.
Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24: 253-62.
3.
Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-24.
4.
Rau RE, Dreyer ZA, Choi MR, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegasparaginase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2018; 65: 10.1002/pbc.26873.
5.
van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica 2016; 101: 279-85.
6.
Burke MJ, Devidas M, Maloney K, et al. Severe peg-asparaginase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials. Leuk Lymphoma 2018; 59: 1624-33.
7.
Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527-33.
8.
Bonno M, Kawasaki H, Hori H, et al. Rapid desensitization for L-asparaginase hypersensitivity. J Allergy Clin Immunol 1998; 101: 571-2.
9.
Soyer OU, Aytac S, Tuncer A, et al. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. J Allergy Clin Immunol 2009; 123: 895-9.
10.
Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102: 179-87.
11.
Ruggiero A, Triarico S, Trombatore G, et al. Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer. Eur J Clin Pharmacol 2013; 69: 1739-46.
12.
Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114: 371-6.
13.
Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006; 6: 476-81.
14.
Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev 2013; 32: 723-61.
15.
Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 199-205.
16.
Salzer W, Seibel N, Smith M. Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Opin Biol Ther 2012; 12: 1407-14.
17.
Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992; 70: 201-6.
18.
BurkeMJ, DevidasM, MaloneyK, et al. Severe pegaspargase hypersensitivity reaction rates (grade >/ = 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials. Leuk Lymphoma 2018; 59: 1624-33.
19.
Nguyen MHN, Memken A, Sriaroon P, et al. A 12-step desensitization protocol for calaspargase Pegol-mknl. J Pediatr Pharmacol Ther 2025; 30: 133-7.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
